A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moderate to severe plaque psoriasis.

Trial Profile

A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moderate to severe plaque psoriasis.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Calcium monoethyl fumarate/dimethyl fumarate/magnesium monoethyl fumarate/zinc monoethyl fumarate
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms BRIDGE
  • Sponsors Almirall S.A.
  • Most Recent Events

    • 28 Sep 2016 Results published in Almirall media release.
    • 28 Sep 2016 Primary endpoint has been met. (Psoriasis Area and Severity Index score 75% (PASI 75)), as per Almirall media release.
    • 28 Sep 2016 According to Almirall media release, results from this study will be presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress. This study has also accepted for publication in the in the British Journal of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top